Action Ultragenyx Pharmaceutical - 0LIF

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

64,79

Prix Achat

0,00

Prix Vente

0,00

Volume échangé

854

0,00 Fourchette du Jour 0,00

64,79 Plage de 52 semaines 64,79

Cap du marché

5,32B

Clôture Veille

64,79

Ouverture

Dernière Transaction

41.58

(O)

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

582

Actions en circulation

82 114 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-5,62

Bénéfice par action (BPA)

-7,39

Chiffre d'affairess

434,25M

Bénéfice net

-606,64M

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.ultragenyx.com

Siège social

Wilmington, Delaware, USA

Fondé

Ultragenyx Pharmaceutical Inc est coté dans le secteur Pharmaceutical Preparations de la London Stock Exchange avec le ticker 0LIF. Le dernier cours de clôture d'Ultragenyx Pharmaceutical était de US$64,79. Au cours de la dernière année, les actions de Ultragenyx Pharmaceutical ont été négociées dans une fourchette de prix de US$ 64,79 à US$ 64,79.

Ultragenyx Pharmaceutical compte actuellement 82 114 000 actions en circulation. La capitalisation boursière d'Ultragenyx Pharmaceutical est de US$5,32 milliard. Ultragenyx Pharmaceutical a un ratio cours/bénéfice (ratio PE) de -5.62.

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH) LONDON, Dec. 20, 2024 (GLOBE...

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho) Evkeeza es un medicamento...

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia...

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) For the...

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH) Evkeeza è un farmaco, primo nel...

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein Evkeeza® ist das erste von der U.S. Food and Drug...

MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy

MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy NOVATO, Calif., Sept. 09, 2021 (GLOBE...

Période	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	64.79	64.79	64.79	34	64.79	DE
4	64.79	64.79	64.79	249	64.79	DE
12	64.79	64.79	64.79	582	64.79	DE
26	64.79	64.79	64.79	390	64.79	DE
52	64.79	64.79	64.79	326	64.79	DE
156	64.79	64.79	64.79	506	64.79	DE
260	64.79	64.79	64.79	319	64.79	DE

0LIF - Frequently Asked Questions (FAQ)

What is the current Ultragenyx Pharmaceutical share price?

The current share price of Ultragenyx Pharmaceutical is US$ 64,79

How many Ultragenyx Pharmaceutical shares are in issue?

Ultragenyx Pharmaceutical has 82 114 000 shares in issue

What is the market cap of Ultragenyx Pharmaceutical?

The market capitalisation of Ultragenyx Pharmaceutical is USD 5,32B

What is the 1 year trading range for Ultragenyx Pharmaceutical share price?

Ultragenyx Pharmaceutical has traded in the range of US$ 64,79 to US$ 64,79 during the past year

What is the PE ratio of Ultragenyx Pharmaceutical?

The price to earnings ratio of Ultragenyx Pharmaceutical is -5,62

What is the cash to sales ratio of Ultragenyx Pharmaceutical?

The cash to sales ratio of Ultragenyx Pharmaceutical is 7,85

What is the reporting currency for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical reports financial results in USD

What is the latest annual turnover for Ultragenyx Pharmaceutical?

The latest annual turnover of Ultragenyx Pharmaceutical is USD 434,25M

What is the latest annual profit for Ultragenyx Pharmaceutical?

The latest annual profit of Ultragenyx Pharmaceutical is USD -606,64M

What is the registered address of Ultragenyx Pharmaceutical?

The registered address for Ultragenyx Pharmaceutical is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801

What is the Ultragenyx Pharmaceutical website address?

The website address for Ultragenyx Pharmaceutical is www.ultragenyx.com

Which industry sector does Ultragenyx Pharmaceutical operate in?

Ultragenyx Pharmaceutical operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
TCFTheracryf Plc	0,725p (38,10%)	7,56M
NMTNeometals Ltd	3,50p (27,27%)	346,81k
SCHOScholium Group Plc	44,00p (25,71%)	30,65k
FABFusion Antibodies Plc	10,15p (24,54%)	3,34M
PYXPyx Resources Limited	3,49p (22,24%)	8,43k
TM1Technology Minerals Plc	0,125p (-24,24%)	37,21M
QUIZQuiz Plc	0,70p (-18,60%)	3,67M
SYMESupply@me Capital Plc	0,003p (-17,81%)	168,35M
OBDOxford Biodynamics Plc	1,20p (-14,29%)	827,83k
ZENZenith Energy Ltd.	5,25p (-13,93%)	5,39M
TRPTower Resources Plc	0,0395p (5,33%)	539,51M
CPXCap-xx Limited	0,1825p (1,39%)	494M
NTVONativo Resources Plc	0,0019p (0,00%)	320,16M
DGIDg Innovate Plc	0,0225p (-13,46%)	208,21M
ENETEthernity Networks Ltd	0,1125p (2,27%)	207,56M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Ultragenyx Pharmaceutical Inc (0LIF)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Ultragenyx Pharmaceutical Inc

0LIF Dernières nouvelles

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein

MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

0LIF - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Ultragenyx Pharmaceutical Inc (0LIF) Cours

Ultragenyx Pharmaceutical Inc (0LIF)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Ultragenyx Pharmaceutical Inc

0LIF Dernières nouvelles

0LIF - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application